Singapore, Feb. 10 -- China-based Innovent Biologics, Inc. has announced a strategic collaboration with Eli Lilly and Company, in the US, to advance novel medicines in oncology and immunology. This agreement marks the seventh collaboration between the two companies, deepening a longstanding and productive partnership to deliver new medicines for patients worldwide.

The collaboration's unique structure also establishes a new model for Innovent to accelerate the global development of its innovative pipeline.

Under the collaboration, the companies will leverage their complementary strengths to accelerate global development of novel medicines.Innovent, drawing on its robust antibody technology platforms and efficient clinical execution, wil...